Smithers Announces New Environmental Risk Sciences President
Smithers, a leading provider of testing, consulting, information, and compliance services, announces the appointment of Dr. Stewart B. Jacobson, DVM, DACVP, as President of the Smithers Environmental Risk Sciences Division.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005968/en/
Dr. Stewart B. Jacobson, DVM, DACVP, President, Smithers Environmental Risk Sciences Division. (Photo: Business Wire)
Stewart has responsibility for operations and business strategy in North America, the United Kingdom, Europe, and Asia Pacific, overseeing Ecotoxicology, Environmental Fate, Plant and Animal Metabolism, and Chemistry services for the pharmaceutical, crop protection, and industrial and specialty chemical industries. He joins Smithers with over 20 years in toxicology and preclinical research, with roles ranging from staff pathologist to the leader of large multi-site contract research organizations (CROs).
“Stewart is a strategic innovator who is highly respected in the industry for scientific excellence and delivery of services that meet client expectations,” said Susan Shepherd, Group President, Smithers. “His breadth of leadership experience, understanding of regulated markets, and expertise in managing global operations will reinforce our commitment to deliver accurate data, on time, through high-touch relationships.”
Stewart earned his Bachelor of Science in Engineering/Computer Science from University of Illinois, and his Doctor of Veterinary Medicine (DVM) from Tufts University. After completing a residency at the University of Connecticut, he was certified as a Diplomate of the American College of Veterinary Pathologists (DACVP). He is a member of the Society of Toxicologic Pathologists and the Society of Cardiovascular Pathologists. His previous roles included high-level leadership positions at Inotiv, Battelle Memorial Institute, SNBL, Charles River Laboratories, and Covance Laboratories. Prior to his roles in pharmaceutical and medical device testing, he was a software engineer and entrepreneur focused on developing computer models for the space shuttle and building software engineering systems for aerospace and engineering applications.
For more information about Smithers, please visit https://www.smithers.com/
Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services. With laboratories and operations in North America, Europe, and Asia, Smithers supports customers in the transportation, life science, packaging, materials, components, consumer, dry commodities, and energy industries. Smithers delivers accurate data, on time, with high touch, by integrating science, technology, and business expertise, so customers can innovate with confidence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Glenn G. Goldney
Executive Vice President of Sales & Marketing
+1 (330) 203-2188
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS to Launch an Infrastructure Region in Mexico26.2.2024 15:50:00 CET | Press release
Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced plans to launch an AWS infrastructure Region in Mexico by early 2025. The new AWS Mexico (Central) Region will give developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, greater choice for running their applications and serving end users from data centers located in Mexico, ensuring that customers who want to store their content in Mexico can do so. As part of its long-term commitment to Latin America, AWS is planning to invest more than $5 billion (approx. MXN $85 billion) in Mexico over 15 years. The upcoming AWS Mexico Region is the latest in AWS’s ongoing investments in Mexico to provide customers with advanced and secure cloud technologies. For more information about AWS Global Infrastructure, visit aws.amazon.com/about-aws/global-infrastructure. “Cloud services are an essential part of everyday life, helping us to digitally and econo
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair26.2.2024 15:19:00 CET | Press release
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma). Dr. Donnenfeld joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® canalicular gel. The FDA-cleared hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system. “Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market. With over 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and catarac
Adtran recognized among STL Partners’ top 100 edge computing companies for 202426.2.2024 14:00:00 CET | Press release
Adtran today announced that it has been recognized as one of STL Partners’ top 100 edge computing companies for 2024, marking its second consecutive year of inclusion on the list. The acknowledgment reaffirms Adtran’s substantial contributions to the sector and highlights its role as a leader, driving innovation amidst the quickly evolving edge computing landscape. This leadership is increasingly vital as more enterprises and service providers seek options beyond centrally deployed, hyperscale clouds to support their business requirements of reducing hosting and backhaul costs, improving service performance and security, and accelerating time to market. This is especially true for the next wave of AI and IoT applications being deployed in various industries, such as manufacturing, transportation, logistics, healthcare, finance, media, retail and the public sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226247955/e
Vantage Data Centers Names Two New Regional Presidents to Support Market Growth Amidst Booming Cloud and AI Demand26.2.2024 14:00:00 CET | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced the appointments of Dana Adams and David Howson who will serve as regional presidents of North America and EMEA, respectively. The company also announced that Antoine Boniface, who has served as president of EMEA for the past four years, will take on a new role as chief commercial officer for the region. These appointments come as the company enters 2024 positioned for another year of significant growth and expansion across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226667521/en/ Dana Adams has joined Vantage Data Centers as President, North America. (Photo: Business Wire) Adams joins Vantage’s executive leadership team as president of North America, bringing nearly 18 years of experience in the data center sector to the company. Based in Denver, she will oversee the region’s growth, including market developm
Pulmonx Announces Treatment of the First Patient with the AeriSeal ® System in CONVERT II Pivotal Trial26.2.2024 14:00:00 CET | Press release
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openings in the lung fissures, or walls between the lung lobes. The AeriSeal System is designed to occlude these naturally occurring openings in a lobe targeted for bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves. Pulmonx received a staged IDE approval by the Food and Drug Administration (FDA) to commence the CONVERT II Pivotal Trial for the AeriSeal System in late 2023. The goal of the CONVERT II Piv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom